公开(公告)号：EP2486054A4

公开(公告)日：2013-09-11

申请号：EP10822829

申请日：2010-10-12

申请人： UNIV EMORY ,  UNIV CHICAGO

发明人： WRAMMERT JENS ,  AHMED RAFI ,  WILSON PATRICK

IPC分类号： C07K16/10 ,  A61K39/42 ,  A61P31/16 ,  C12N15/13

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76

公开(公告)号：EP2663334A4

公开(公告)日：2016-01-13

申请号：EP12734165

申请日：2012-01-10

申请人： UNIV EMORY ,  UNIV CHICAGO

发明人： AHMED RAFI ,  WRAMMERT JENS ,  WILSON PATRICK C

IPC分类号： A61K39/42 ,  A61P31/16 ,  C07K16/10

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

公开(公告)号：EP2768858A4

公开(公告)日：2015-06-03

申请号：EP12841118

申请日：2012-10-18

申请人： UNIV EMORY ,  UNIV CHICAGO

发明人： AHMED RAFI ,  WRAMMERT JENS ,  WILSON PATRICK C

IPC分类号： C07K16/10 ,  G01N33/569

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2469/00

摘要： Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.

公开(公告)号：EP2318002A4

公开(公告)日：2012-11-28

申请号：EP09805516

申请日：2009-08-05

申请人： UNIV EMORY

发明人： AHMED RAFI ,  LARSEN CHRISTIAN P ,  ARAKI KOICHI

IPC分类号： A61K31/4745 ,  A61K39/00 ,  A61K39/12 ,  A61P31/12 ,  A61P35/00

CPC分类号： A61K31/436 ,  A61K31/4745 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2730/10134 ,  C12N2740/13023 ,  C12N2740/13043 ,  C12N2760/10034 ,  C12N2770/10022 ,  A61K2300/00

公开(公告)号：EP2342226A4

公开(公告)日：2012-11-28

申请号：EP09816950

申请日：2009-09-25

申请人： DANA FARBER CANCER INST INC ,  UNIV EMORY

发明人： FREEMAN GORDON J ,  AHMED RAFI ,  JONES TIMOTHY D ,  CARR FRANCIS J ,  GREGSON JAMES P

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

公开(公告)号：EP2370593A4

公开(公告)日：2012-09-05

申请号：EP09829832

申请日：2009-11-27

申请人： UNIV EMORY ,  DANA FARBER CANCER INST INC

发明人： AHMED RAFI ,  AMARA RAMA ,  VELU VIJAYAKUMAR ,  TITANJI KEHMIA ,  FREEMAN GORDON

IPC分类号： C12Q1/02 ,  A61K31/7105 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00 ,  C12N5/0781 ,  G01N33/50

CPC分类号： G01N33/5052 ,  A61K31/7105 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55516 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2760/10034 ,  G01N33/5088 ,  G01N33/56966 ,  G01N2333/52 ,  G01N2800/26 ,  A61K2300/00

摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.

摘要翻译： 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强对感染剂或肿瘤细胞特异性的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染的受试者，例如持续感染。 此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。 还公开了用于测定施用PD-1拮抗剂的受试者中PD-1拮抗剂的功效的方法。 在一些实施方案中，这些方法包括测量来自施用PD-1拮抗剂的受试者的样品中记忆B细胞的增殖。